Elanco Animal Health (ELAN) Current Deferred Revenue (2017 - 2026)

Elanco Animal Health has reported Current Deferred Revenue for 10 years, with the latest figure at $400.0 million in Q1 2026.

• Quarterly Current Deferred Revenue rose 25.39% year-over-year to $400.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $400.0 million (up 25.39% YoY) and the FY2025 annual result came in at $416.0 million, up 25.3% from the prior year.
• Current Deferred Revenue fell to $400.0 million in Q1 2026 per ELAN's latest filing, from $416.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $416.0 million in Q4 2025 and troughed at $284.0 million in Q2 2022.
• A 5-year average of $341.8 million and a median of $332.0 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2026: Current Deferred Revenue retreated 10.27% in 2022, then climbed 25.39% in 2026.
• Over 5 years, Current Deferred Revenue stood at $324.0 million in 2022, then advanced by 13.27% to $367.0 million in 2023, then fell by 9.54% to $332.0 million in 2024, then advanced by 25.3% to $416.0 million in 2025, then decreased by 3.85% to $400.0 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $400.0 million, $416.0 million, and $376.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.